GNFT Fundamental Analysis - GENFIT-ADR

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to GNFT. GNFT was compared to 536 industry peers in the Biotechnology industry. Both the profitability and financial health of GNFT have multiple concerns. GNFT has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

GNFT had negative earnings in the past year.

GNFT had a negative operating cash flow in the past year.

The reported net income has been mixed in the past 5 years: GNFT reported negative net income in multiple years.

In multiple years GNFT reported negative operating cash flow during the last 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -17.89%, GNFT is in the better half of the industry, outperforming 79.10% of the companies in the same industry.

With a Return On Equity value of -73.87%, GNFT perfoms like the industry average, outperforming 54.66% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-17.89%
ROE	-73.87%
ROIC	N/A

ROA(3y)-8.87%

ROA(5y)-10.74%

ROE(3y)-21.81%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

GNFT's Profit Margin has declined in the last couple of years.

GNFT's Operating Margin has declined in the last couple of years.

With an excellent Gross Margin value of 95.42%, GNFT belongs to the best of the industry, outperforming 94.59% of the companies in the same industry.

In the last couple of years the Gross Margin of GNFT has remained more or less at the same level.

The Profit Margin and Operating Margin are not available for GNFT so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	95.42%

OM growth 3Y-50.59%

OM growth 5YN/A

PM growth 3Y-69.99%

PM growth 5YN/A

GM growth 3Y-0.4%

GM growth 5Y0.52%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

GNFT does not have a ROIC to compare to the WACC, probably because it is not profitable.

GNFT has more shares outstanding than it did 1 year ago.

The number of shares outstanding for GNFT has been increased compared to 5 years ago.

Compared to 1 year ago, GNFT has a worse debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -1.56, we must say that GNFT is in the distress zone and has some risk of bankruptcy.

GNFT's Altman-Z score of -1.56 is in line compared to the rest of the industry. GNFT outperforms 52.24% of its industry peers.

A Debt/Equity ratio of 0.09 indicates that GNFT is not too dependend on debt financing.

The Debt to Equity ratio of GNFT (0.09) is worse than 63.25% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.09
Debt/FCF	N/A
Altman-Z	-1.56

ROIC/WACCN/A

WACC7.05%

2.3 Liquidity

A Current Ratio of 3.74 indicates that GNFT has no problem at all paying its short term obligations.

Looking at the Current ratio, with a value of 3.74, GNFT is in line with its industry, outperforming 43.66% of the companies in the same industry.

GNFT has a Quick Ratio of 3.74. This indicates that GNFT is financially healthy and has no problem in meeting its short term obligations.

Looking at the Quick ratio, with a value of 3.74, GNFT is in line with its industry, outperforming 45.71% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	3.74
Quick Ratio	3.74

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

GNFT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -327.32%.

GNFT shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -70.77% yearly.

Looking at the last year, GNFT shows a very negative growth in Revenue. The Revenue has decreased by -45.94% in the last year.

GNFT shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.61% yearly.

EPS 1Y (TTM)-327.32%

EPS 3Y-70.77%

EPS 5YN/A

EPS Q2Q%-139.82%

Revenue 1Y (TTM)-45.94%

Revenue growth 3Y-6.06%

Revenue growth 5Y11.61%

Sales Q2Q%-39.51%

3.2 Future

Based on estimates for the next years, GNFT will show a very negative growth in Earnings Per Share. The EPS will decrease by -29.26% on average per year.

The Revenue is expected to decrease by -2.23% on average over the next years.

EPS Next Y15.82%

EPS Next 2Y-94%

EPS Next 3Y-41.45%

EPS Next 5Y-29.26%

Revenue Next Year-8.28%

Revenue Next 2Y-21.93%

Revenue Next 3Y-9.85%

Revenue Next 5Y-2.23%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

GNFT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GNFT. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A cheap valuation may be justified as GNFT's earnings are expected to decrease with -41.45% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-94%

EPS Next 3Y-41.45%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

GNFT does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

GENFIT-ADR

NASDAQ:GNFT (10/9/2025, 1:50:12 PM)

4.45

+0.54 (+13.81%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)09-22 2025-09-22

Earnings (Next)11-20 2025-11-20

Inst Owners0.76%

Inst Owner Change0%

Ins Owners0.18%

Ins Owner ChangeN/A

Market Cap222.51M

Analysts90.77

Price Target10.12 (127.42%)

Short Float %0.07%

Short Ratio6.57

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)-5.89%

PT rev (3m)-10.11%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)-25.17%

EPS NY rev (3m)715.54%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)-1.91%

Revenue NY rev (3m)-11.07%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	4.21
P/FCF	N/A
P/OCF	N/A
P/B	3.65
P/tB	90.02
EV/EBITDA	N/A

EPS(TTM)-0.9

EYN/A

EPS(NY)-0.75

Fwd EYN/A

FCF(TTM)-0.16

FCFYN/A

OCF(TTM)-0.08

OCFYN/A

SpS1.06

BVpS1.22

TBVpS0.05

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-17.89%
ROE	-73.87%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	95.42%
FCFM	N/A

ROA(3y)-8.87%

ROA(5y)-10.74%

ROE(3y)-21.81%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3Y-50.59%

OM growth 5YN/A

PM growth 3Y-69.99%

PM growth 5YN/A

GM growth 3Y-0.4%

GM growth 5Y0.52%

F-Score2

Asset Turnover0.21

Health

		Industry Rank	Sector Rank
Debt/Equity	0.09
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	188.46%
Cap/Sales	7.33%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	3.74
Quick Ratio	3.74
Altman-Z	-1.56

F-Score2

WACC7.05%

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-327.32%

EPS 3Y-70.77%

EPS 5YN/A

EPS Q2Q%-139.82%

EPS Next Y15.82%

EPS Next 2Y-94%

EPS Next 3Y-41.45%

EPS Next 5Y-29.26%

Revenue 1Y (TTM)-45.94%

Revenue growth 3Y-6.06%

Revenue growth 5Y11.61%

Sales Q2Q%-39.51%

Revenue Next Year-8.28%

Revenue Next 2Y-21.93%

Revenue Next 3Y-9.85%

Revenue Next 5Y-2.23%

EBIT growth 1Y-216.85%

EBIT growth 3Y-53.58%

EBIT growth 5YN/A

EBIT Next Year-6.17%

EBIT Next 3Y-0.9%

EBIT Next 5YN/A

FCF growth 1Y87.25%

FCF growth 3Y-47.27%

FCF growth 5YN/A

OCF growth 1Y93.33%

OCF growth 3Y-46.21%

OCF growth 5YN/A

GENFIT-ADR (GNFT) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens